SCHEMBL25690437

SCHEMBL25690437

Cc1nc(C(=O)NC2CC(O)C2)ccc1I

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRM5 P08912 1/20 0.40
▸ BRD4 O60885 1/20 0.40
▸ HPGDS O60760 1/20 0.39
▸ SCN9A Q15858 4/20 0.39
▸ SCN7A Q01118 1/20 0.39
▸ KCNH2 Q12809 1/20 0.39
▸ SCN5A Q14524 1/20 0.39
▸ GRM5 P41594 2/20 0.38
▸ HSD11B1 P28845 1/20 0.36
▸ DPP4 P27487 2/20 0.36
▸ CCNA2 P20248 2/20 0.35
▸ CDK2 P24941 2/20 0.35
▸ CDK5 Q00535 2/20 0.35
▸ CDK5R1 Q15078 2/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ CNR1 P21554 2/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25690684 1.00 CHRM5 (0.40) CHRM5BRD4HPGDSSCN9ASCN7A
SCHEMBL25690606 0.89 GRM5 (0.38) GRM5HSD11B1DPP4CCNA2CDK2
SCHEMBL25690421 0.87 DPP4 (0.45) GRM5HSD11B1DPP4ALDH1A1CNR1
SCHEMBL25690427 0.84 BRD4 (0.37) BRD4SCN9AGRM5DPP4CCNA2
SCHEMBL25690611 0.84 BRD4 (0.37) BRD4SCN9AGRM5DPP4CCNA2
SCHEMBL25690689 0.82 CD38 (0.48) DPP4CNR1NPC1RAB9A
SCHEMBL25690436 0.82 ALDH1A1 (0.39) GRM5HSD11B1DPP4ALDH1A1NPC1
SCHEMBL25690431 0.81 SCN9A (0.43) SCN9ASCN7AKCNH2SCN5AGRM5
SCHEMBL25690429 0.81 CNR2 (0.48) BRD4HPGDSSCN9ADPP4NPC1
SCHEMBL25690440 0.80 CHRNB2 (0.45) HSD11B1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023122140-A1 PARP1 INHIBITORS SYNNOVATION THERAPEUTICS, INC. (US) 2023-06-29 — — WO disclosed
Send feedback